Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Aug 3, 2012

NEW YORK (GenomeWeb News) – As of July 26, Joffre Baker has left his position as chief scientific officer of Genomic Health and has become a senior fellow at the company. Effective the same date, Chief Medical Officer Steven Shak has taken on responsibilities for managing Genomic Health's research operations that were previously managed by Baker. In addition to being theCMO, Shak has the additional title of executive VP of research and development.

Genomic Health's board of directors has also elected Felix Baker as a member of the board. Baker is a managing partner and co-founder of Baker Brothers Investments.

Firefly BioWorks said this week that Kip Miller has been elected to serve on the company's board of directors. Miller recently was president of Genetic Systems at Life Technologies, where he was responsible for the Applied Biosystems DNA sequencing business and development of forensics and HLA diagnostics applications.

During his term at Life Technologies, Miller also was senior VP of the Biodiscovery and Enabling Technologies Divisions at Invitrogen. Miller also previously served as VP and GM of BD Biosciences, where he was responsible for development of the flow cytometry business and commercial operations in the Americas.

Genome British Columbia said recently that John Shepherd has been appointed to serve on its board of directors. Shepherd currently is director of the Leukemia/Bone Marrow Transplant Program of BC, and is a clinical professor of medicine at the University of British Columbia.

Biomarker developer Abcodia said this week that Claire Hooper has been appointed to serve on its board of directors as a non-executive director. Hooper has been a senior director in R&D at PerkinElmer and was founder and director of Cambridge Imaging, which was acquired by PerkinElmer.

Blaine Bowman has joined the board of directors at Altera. Bowman currently is on the board of directors at Illumina, and he formerly was president, CEO, and chairman of the board of directors for the chromatography technology company Dionex, where he had a 28-year career.

Kevin King has been named to serve on the board of directors at medical diagnostics company iRhythm Technologies. King formerly was president and CEO at Affymetrix, and he held the same position at Thomson Healthcare and was an executive at GE Healthcare and Hewlett Packard's Medical Products Group.

Response Biomedical said this week that Jonathan Wang has been appointed to the company's board of directors. Wang, who did a previous stint as a director at Response Biomedical in 2010 and 2011 and serves on the board at ForteBio, is a senior managing director at Orbimed, and he is a co-founder of that company's Asia-focused venture capital fund. He previously was a GM at Burrill Greater China Group and he worked for other venture capital funds focused on Asia.

Issam Zineh has been hired to be director of the US Food and Drug Administration's Office of Clinical Pharmacology, a promotion from his most recent position as associate director for genomics for the same office.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.